From the Toronto Star:
Bextra, an anti-inflammatory drug for arthritis sufferers, will not be allowed back on the Canadian market.
Based on recommendations from an expert safety panel, Health Canada said yesterday the cardiovascular risks of the drug, including heart attack and stroke, outweighed its benefits. ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment